Whitney & Co’s Heron Therapeutics HRTX Stock Holding History

Whitney & Co’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-45	Closed	-$1K	–	256
2018 Q3	$1K	Buy	+45	New	+$1.68K	﹤0.01%	505

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Whitney & Co's HRTX Position: Q4 2018 in Review

Whitney & Co sold out of Heron Therapeutics (HRTX) in Q4 2018, closing a stake of 45 shares — an estimated $1K sold.

Whitney & Co first reported a position in HRTX in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2018.

Whitney & Co reported no remaining Heron Therapeutics position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 45 Heron Therapeutics shares in Q4 2018, an estimated $1K.
Whitney & Co first reported a position in Heron Therapeutics in Q3 2018 and held it in 1 quarter.
Whitney & Co's Heron Therapeutics position peaked at $1K in Q3 2018.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.